CA1298552C - Solutions d'hemoglobine purifiee et methode permettant de les produire - Google Patents

Solutions d'hemoglobine purifiee et methode permettant de les produire

Info

Publication number: CA1298552C
Authority: CA; Canada
Prior art keywords: hemoglobin; degrees; heating; solution; reducing agent
Prior art date: 1988-02-04
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA000558145A

Other languages

English (en)

Inventor

Timothy N. Estep

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Baxter International Inc

Original Assignee

Baxter International Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-02-04

Filing date

1988-02-04

Publication date

1992-04-07

1988-02-04 Application filed by Baxter International Inc filed Critical Baxter International Inc

1988-02-04 Priority to CA000558145A priority Critical patent/CA1298552C/fr

1992-04-07 Application granted granted Critical

1992-04-07 Publication of CA1298552C publication Critical patent/CA1298552C/fr

2009-04-07 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

108010054147 Hemoglobins Proteins 0.000 title claims abstract description 232
102000001554 Hemoglobins Human genes 0.000 title claims abstract description 232
238000000034 method Methods 0.000 title claims abstract description 108
238000010438 heat treatment Methods 0.000 claims abstract description 65
102000004169 proteins and genes Human genes 0.000 claims abstract description 51
108090000623 proteins and genes Proteins 0.000 claims abstract description 51
241000700605 Viruses Species 0.000 claims abstract description 50
239000003638 chemical reducing agent Substances 0.000 claims abstract description 43
239000000243 solution Substances 0.000 claims description 118
239000000203 mixture Substances 0.000 claims description 44
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 38
239000001301 oxygen Substances 0.000 claims description 37
229910052760 oxygen Inorganic materials 0.000 claims description 37
230000003612 virological effect Effects 0.000 claims description 28
INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical group N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 claims description 27
239000012528 membrane Substances 0.000 claims description 22
108010002255 deoxyhemoglobin Proteins 0.000 claims description 17
239000007789 gas Substances 0.000 claims description 16
239000011261 inert gas Substances 0.000 claims description 16
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims description 15
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 15
GRWZHXKQBITJKP-UHFFFAOYSA-L dithionite(2-) Chemical group [O-]S(=O)S([O-])=O GRWZHXKQBITJKP-UHFFFAOYSA-L 0.000 claims description 13
239000003795 chemical substances by application Substances 0.000 claims description 11
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
230000002779 inactivation Effects 0.000 claims description 10
229910052786 argon Inorganic materials 0.000 claims description 8
238000006243 chemical reaction Methods 0.000 claims description 8
238000009792 diffusion process Methods 0.000 claims description 8
230000000415 inactivating effect Effects 0.000 claims description 8
-1 sulfoxy Chemical group 0.000 claims description 8
229910052757 nitrogen Inorganic materials 0.000 claims description 7
239000007864 aqueous solution Substances 0.000 claims description 6
230000001376 precipitating effect Effects 0.000 claims description 6
108010024636 Glutathione Proteins 0.000 claims description 5
229940072107 ascorbate Drugs 0.000 claims description 5
235000010323 ascorbic acid Nutrition 0.000 claims description 5
239000011668 ascorbic acid Substances 0.000 claims description 5
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 5
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 4
150000001875 compounds Chemical class 0.000 claims description 4
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims description 4
239000002244 precipitate Substances 0.000 claims description 4
229910052783 alkali metal Inorganic materials 0.000 claims description 3
150000001340 alkali metals Chemical group 0.000 claims description 3
230000005587 bubbling Effects 0.000 claims description 2
239000000463 material Substances 0.000 claims description 2
125000003396 thiol group Chemical group [H]S* 0.000 claims description 2
WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 claims 3
LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 claims 3
230000003635 deoxygenating effect Effects 0.000 abstract description 3
235000018102 proteins Nutrition 0.000 description 45
150000002500 ions Chemical class 0.000 description 25
210000004369 blood Anatomy 0.000 description 22
239000008280 blood Substances 0.000 description 22
210000004027 cell Anatomy 0.000 description 19
101100284769 Drosophila melanogaster hemo gene Proteins 0.000 description 17
210000004379 membrane Anatomy 0.000 description 16
238000006392 deoxygenation reaction Methods 0.000 description 12
108010064719 Oxyhemoglobins Proteins 0.000 description 11
239000000047 product Substances 0.000 description 10
108010061951 Methemoglobin Proteins 0.000 description 9
239000000523 sample Substances 0.000 description 9
230000000694 effects Effects 0.000 description 8
210000003743 erythrocyte Anatomy 0.000 description 7
238000000862 absorption spectrum Methods 0.000 description 6
239000002253 acid Substances 0.000 description 5
239000000872 buffer Substances 0.000 description 5
238000010790 dilution Methods 0.000 description 5
239000012895 dilution Substances 0.000 description 5
238000000746 purification Methods 0.000 description 5
JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 5
238000001228 spectrum Methods 0.000 description 5
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
239000000427 antigen Substances 0.000 description 4
102000036639 antigens Human genes 0.000 description 4
108091007433 antigens Proteins 0.000 description 4
230000004071 biological effect Effects 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
150000003278 haem Chemical class 0.000 description 4
238000001556 precipitation Methods 0.000 description 4
229910052708 sodium Inorganic materials 0.000 description 4
239000011734 sodium Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
238000000108 ultra-filtration Methods 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
241000726306 Irus Species 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000000654 additive Substances 0.000 description 3
150000001413 amino acids Chemical class 0.000 description 3
238000011109 contamination Methods 0.000 description 3
238000004925 denaturation Methods 0.000 description 3
230000036425 denaturation Effects 0.000 description 3
238000013461 design Methods 0.000 description 3
238000005187 foaming Methods 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
238000012545 processing Methods 0.000 description 3
239000012064 sodium phosphate buffer Substances 0.000 description 3
239000003381 stabilizer Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
INZBQWPDNWVYFR-OWOJBTEDSA-N 3,5-dibromo-2-[(e)-4-(2,4-dibromo-6-carboxyphenoxy)-4-oxobut-2-enoyl]oxybenzoic acid Chemical compound OC(=O)C1=CC(Br)=CC(Br)=C1OC(=O)\C=C\C(=O)OC1=C(Br)C=C(Br)C=C1C(O)=O INZBQWPDNWVYFR-OWOJBTEDSA-N 0.000 description 2
OQEBBZSWEGYTPG-UHFFFAOYSA-N 3-Aminobutanoic acid Natural products CC(N)CC(O)=O OQEBBZSWEGYTPG-UHFFFAOYSA-N 0.000 description 2
102000009027 Albumins Human genes 0.000 description 2
108010088751 Albumins Proteins 0.000 description 2
101100536354 Drosophila melanogaster tant gene Proteins 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
239000002518 antifoaming agent Substances 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
230000003078 antioxidant effect Effects 0.000 description 2
235000006708 antioxidants Nutrition 0.000 description 2
UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
244000309464 bull Species 0.000 description 2
230000006037 cell lysis Effects 0.000 description 2
239000000975 dye Substances 0.000 description 2
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000011521 glass Substances 0.000 description 2
239000012535 impurity Substances 0.000 description 2
238000011534 incubation Methods 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
230000002458 infectious effect Effects 0.000 description 2
230000003993 interaction Effects 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
239000003446 ligand Substances 0.000 description 2
229920002521 macromolecule Polymers 0.000 description 2
239000002609 medium Substances 0.000 description 2
WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
230000001590 oxidative effect Effects 0.000 description 2
239000008188 pellet Substances 0.000 description 2
239000000049 pigment Substances 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
239000011591 potassium Substances 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
125000002050 pyridoxal group Chemical group 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
239000002356 single layer Substances 0.000 description 2
239000001488 sodium phosphate Substances 0.000 description 2
229910000162 sodium phosphate Inorganic materials 0.000 description 2
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
238000003860 storage Methods 0.000 description 2
229910052717 sulfur Inorganic materials 0.000 description 2
239000000725 suspension Substances 0.000 description 2
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
NWXMGUDVXFXRIG-NAOJVREFSA-N (4s,4as,5as,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2C(O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-NAOJVREFSA-N 0.000 description 1
NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
QWCKQJZIFLGMSD-UHFFFAOYSA-N 2-Aminobutanoic acid Natural products CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 1
PREOBXYMXLETCA-UHFFFAOYSA-N 2-[4-(2-carboxyphenoxy)-4-oxobutanoyl]oxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1OC(=O)CCC(=O)OC1=CC=CC=C1C(O)=O PREOBXYMXLETCA-UHFFFAOYSA-N 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
241000331231 Amorphocerini gen. n. 1 DAD-2008 Species 0.000 description 1
101100012544 Bacillus subtilis (strain 168) ylmB gene Proteins 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
108010003320 Carboxyhemoglobin Proteins 0.000 description 1
241000040710 Chela Species 0.000 description 1
241000867607 Chlorocebus sabaeus Species 0.000 description 1
241000543381 Cliftonia monophylla Species 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical compound CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 description 1
GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
241001050985 Disco Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
240000002989 Euphorbia neriifolia Species 0.000 description 1
102000001690 Factor VIII Human genes 0.000 description 1
108010054218 Factor VIII Proteins 0.000 description 1
CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
241000710198 Foot-and-mouth disease virus Species 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
206010019791 Hepatitis post transfusion Diseases 0.000 description 1
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
241001527806 Iti Species 0.000 description 1
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
241000948268 Meda Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000353097 Molva molva Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
101150034459 Parpbp gene Proteins 0.000 description 1
241001387976 Pera Species 0.000 description 1
208000000474 Poliomyelitis Diseases 0.000 description 1
LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
206010037742 Rabies Diseases 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
206010042971 T-cell lymphoma Diseases 0.000 description 1
208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
241000347391 Umbrina cirrosa Species 0.000 description 1
240000004543 Vicia ervilia Species 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
229910052785 arsenic Inorganic materials 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
229940000635 beta-alanine Drugs 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229910001424 calcium ion Inorganic materials 0.000 description 1
244000309466 calf Species 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
230000000711 cancerogenic effect Effects 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
231100000357 carcinogen Toxicity 0.000 description 1
239000003183 carcinogenic agent Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000000120 cytopathologic effect Effects 0.000 description 1
238000007872 degassing Methods 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000003599 detergent Substances 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
229910001873 dinitrogen Inorganic materials 0.000 description 1
150000002009 diols Chemical class 0.000 description 1
201000010099 disease Diseases 0.000 description 1
231100000676 disease causative agent Toxicity 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
206010014599 encephalitis Diseases 0.000 description 1
238000002146 exchange transfusion Methods 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
229960003692 gamma aminobutyric acid Drugs 0.000 description 1
102000018146 globin Human genes 0.000 description 1
108060003196 globin Proteins 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
229960002591 hydroxyproline Drugs 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
208000014674 injury Diseases 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
229940001447 lactate Drugs 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
239000007788 liquid Substances 0.000 description 1
150000004668 long chain fatty acids Chemical class 0.000 description 1
230000007774 longterm Effects 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
238000005259 measurement Methods 0.000 description 1
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
229910052753 mercury Inorganic materials 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
239000006916 nutrient agar Substances 0.000 description 1
229960002446 octanoic acid Drugs 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
238000013021 overheating Methods 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
150000002978 peroxides Chemical class 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
235000004252 protein component Nutrition 0.000 description 1
230000029983 protein stabilization Effects 0.000 description 1
NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 1
235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
229940076788 pyruvate Drugs 0.000 description 1
239000000376 reactant Substances 0.000 description 1
238000011160 research Methods 0.000 description 1
238000005070 sampling Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
229940054269 sodium pyruvate Drugs 0.000 description 1
RBWSWDPRDBEWCR-RKJRWTFHSA-N sodium;(2r)-2-[(2r)-3,4-dihydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethanolate Chemical compound [Na+].[O-]C[C@@H](O)[C@H]1OC(=O)C(O)=C1O RBWSWDPRDBEWCR-RKJRWTFHSA-N 0.000 description 1
NGSFWBMYFKHRBD-DKWTVANSSA-M sodium;(2s)-2-hydroxypropanoate Chemical compound [Na+].C[C@H](O)C([O-])=O NGSFWBMYFKHRBD-DKWTVANSSA-M 0.000 description 1
239000008279 sol Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
108010001708 stroma free hemoglobin Proteins 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000005846 sugar alcohols Chemical class 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
101150050634 thiQ gene Proteins 0.000 description 1
HLCHESOMJVGDSJ-UHFFFAOYSA-N thiq Chemical compound C1=CC(Cl)=CC=C1CC(C(=O)N1CCC(CN2N=CN=C2)(CC1)C1CCCCC1)NC(=O)C1NCC2=CC=CC=C2C1 HLCHESOMJVGDSJ-UHFFFAOYSA-N 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
230000008733 trauma Effects 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
238000005406 washing Methods 0.000 description 1

Landscapes

Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

CA000558145A 1988-02-04 1988-02-04 Solutions d'hemoglobine purifiee et methode permettant de les produire Expired - Lifetime CA1298552C (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA000558145A CA1298552C (fr)	1988-02-04	1988-02-04	Solutions d'hemoglobine purifiee et methode permettant de les produire

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA000558145A CA1298552C (fr)	1988-02-04	1988-02-04	Solutions d'hemoglobine purifiee et methode permettant de les produire

Publications (1)

Publication Number	Publication Date
CA1298552C true CA1298552C (fr)	1992-04-07

Family

ID=4137392

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000558145A Expired - Lifetime CA1298552C (fr)	1988-02-04	1988-02-04	Solutions d'hemoglobine purifiee et methode permettant de les produire

Country Status (1)

Country	Link
CA (1)	CA1298552C (fr)

1988
- 1988-02-04 CA CA000558145A patent/CA1298552C/fr not_active Expired - Lifetime

Publication	Publication Date	Title
US4861867A (en)	1989-08-29	Purified hemoglobin solutions and method for making same
US4831012A (en)	1989-05-16	Purified hemoglobin solutions and method for making same
US5281579A (en)	1994-01-25	Purified virus-free hemoglobin solutions and method for making same
Wells et al.	1991	Inactivation of human immunodeficiency virus type 1 by ozone in vitro
EP0290252B1 (fr)	1993-01-27	Substitut du sang pasteurisable, lyophilisable, à base d'hémoglobine
US5189146A (en)	1993-02-23	Pasteurizable, freeze-driable hemoglobin-based blood substitute
US7459535B2 (en)	2008-12-02	Method of forming a polymerized hemoglobin solution from stabilized hemoglobin
JPH04505119A (ja)	1992-09-10	ヒスチジン緩衝の腹膜透析溶液
EP0379534A1 (fr)	1990-08-01	Procede de purification d'hemoglobine reticulee
FI104722B (fi)	2000-03-31	Pyridoksiloidun hemoglobiinin valmistusmenetelmä
RU2337705C2 (ru)	2008-11-10	Растворы полимеризованного гемоглобина с пониженным количеством тетрамера и способ их получения
EP2322207A2 (fr)	2011-05-18	Substitut sanguin à fonction de transport d oxygène, composition pharmaceutique et variantes
CA1298552C (fr)	1992-04-07	Solutions d'hemoglobine purifiee et methode permettant de les produire
CA1258230A (fr)	1989-08-08	Hemoglobine et methode de preparation
US5919907A (en)	1999-07-06	Preparation and utilization of a novel sterile albumin
Aranha-Creado et al.	1998	Clearance of murine leukaemia virus from monoclonal antibody solution by a hydrophilic PVDF microporous membrane filter
EP1419171B1 (fr)	2010-12-22	Synthese d'une solution d'haemoglobine modifi e
SK134398A3 (en)	2001-01-18	Aqueous solution of the pyridoxylated polymerized hemoglobin and method for preparing the same
WO1993017693A1 (fr)	1993-09-16	Compositions albumine-iode utilisee dans la conservation du sang, des tissus et des fluides biologiques
CN101306200A (zh)	2008-11-19	静脉注射用乙型肝炎人免疫球蛋白的制备方法
KR20010099700A (ko)	2001-11-09	무-간질 헤모글로빈의 제조 방법
US7285379B2 (en)	2007-10-23	Artificial oxygen carrier and production method thereof
CN103387613B (zh)	2016-12-28	一种血红蛋白及血红蛋白氧载体病毒灭活的方法
WO1992008478A1 (fr)	1992-05-29	Procede d'amelioration de la stabilite du stockage a long terme de produits d'hemoglobine
US4886779A (en)	1989-12-12	Inactivation of human immunodeficiency virus (HIV) in protein-containing solutions by phenols

Legal Events

Date	Code	Title	Description
2005-04-07	MKLA	Lapsed